abstract |
A novel aspartyl protease inhibitor is provided. The present invention relates to a novel class of sulfonamides that are aspartyl protease inhibitors. In one embodiment, the present invention relates to a novel class of HIV aspartyl proteases characterized by specific structural and physicochemical characteristics. The invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of the invention are particularly well suited to inhibit HIV-1 and HIV-2 protease activity, and as a result, as antiviral agents against HIV-1 and HIV-2 viruses. It can be used advantageously. The present invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of the present invention, and methods for screening compounds for anti-HIV activity. [Selection figure] None |